186 related articles for article (PubMed ID: 17165267)
21. Safety and Efficacy of a Progressively Prolonged Maintenance Interval of Venom Immunotherapy.
Kontou-Fili K; Pitsios C; Kompoti E; Giannakopoulos D; Kouridakis S
Int Arch Allergy Immunol; 2018; 176(1):39-43. PubMed ID: 29649812
[TBL] [Abstract][Full Text] [Related]
22. A modified ultrarush insect venom immunotherapy protocol for children.
Steiss JO; Jödicke B; Lindemann H
Allergy Asthma Proc; 2006; 27(2):148-50. PubMed ID: 16724635
[TBL] [Abstract][Full Text] [Related]
23. Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy.
Pereira-Santos MC; Baptista AP; Melo A; Alves RR; Soares RS; Pedro E; Pereira-Barbosa M; Victorino RM; Sousa AE
Clin Exp Allergy; 2008 Feb; 38(2):291-7. PubMed ID: 18070166
[TBL] [Abstract][Full Text] [Related]
24. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
[TBL] [Abstract][Full Text] [Related]
25. Serum concentration of baseline mast cell tryptase: evidence for a decline during long-term immunotherapy for Hymenoptera venom allergy.
Dugas-Breit S; Przybilla B; Dugas M; Arnold A; Pfundstein G; Küchenhoff H; Ruëff F
Clin Exp Allergy; 2010 Apr; 40(4):643-9. PubMed ID: 20100187
[TBL] [Abstract][Full Text] [Related]
26. Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy.
Mamessier E; Birnbaum J; Dupuy P; Vervloet D; Magnan A
Clin Exp Allergy; 2006 Jun; 36(6):704-13. PubMed ID: 16776670
[TBL] [Abstract][Full Text] [Related]
27. High sensitivity of basophils predicts side-effects in venom immunotherapy.
Kosnik M; Silar M; Bajrovic N; Music E; Korosec P
Allergy; 2005 Nov; 60(11):1401-6. PubMed ID: 16197472
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Safety Profiles of 3 Different Hymenoptera Venom Immunotherapy Protocols: A Retrospective 2-Center Study of 143 Patients.
Pospischil IM; Kagerer M; Cozzio A; Angelova-Fischer I; Guenova E; Ballmer-Weber B; Hoetzenecker W
Int Arch Allergy Immunol; 2020; 181(10):783-789. PubMed ID: 32781451
[TBL] [Abstract][Full Text] [Related]
29. Rapid venom immunotherapy is safe for routine use in the treatment of patients with Hymenoptera anaphylaxis.
Bernstein JA; Kagen SL; Bernstein DI; Bernstein IL
Ann Allergy; 1994 Nov; 73(5):423-8. PubMed ID: 7978535
[TBL] [Abstract][Full Text] [Related]
30. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy.
Alessandrini AE; Berra D; Rizzini FL; Mauro M; Melchiorre A; Rossi F; Spezia D; Stanizzi R; Ricciardi L; Burastero SE
Ann Allergy Asthma Immunol; 2006 Jul; 97(1):92-7. PubMed ID: 16892788
[TBL] [Abstract][Full Text] [Related]
31. Humoral immunological response in patients with venom allergy during specific immunotherapy.
Szymański W; Chyrek-Borowska S
Rocz Akad Med Bialymst; 1995; 40(2):376-82. PubMed ID: 8834621
[TBL] [Abstract][Full Text] [Related]
32. Sublingual desensitization in patients with wasp venom allergy: preliminary results.
Patriarca G; Nucera E; Roncallo C; Aruanno A; Lombardo C; Decinti M; Pascolini L; Milani M; Buonomo A; Schiavino D
Int J Immunopathol Pharmacol; 2008; 21(3):669-77. PubMed ID: 18831935
[TBL] [Abstract][Full Text] [Related]
33. Safety of specific immunotherapy using an ultra-rush induction regimen in bee and wasp allergy.
Bożek A; Kołodziejczyk K
Hum Vaccin Immunother; 2018 Feb; 14(2):288-291. PubMed ID: 29106324
[TBL] [Abstract][Full Text] [Related]
34. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
[TBL] [Abstract][Full Text] [Related]
35. Ultrarush versus semirush initiation of insect venom immunotherapy: a randomized controlled trial.
Brown SG; Wiese MD; van Eeden P; Stone SF; Chuter CL; Gunner J; Wanandy T; Phillips M; Heddle RJ
J Allergy Clin Immunol; 2012 Jul; 130(1):162-8. PubMed ID: 22460067
[TBL] [Abstract][Full Text] [Related]
36. Adverse reactions in venom immunotherapy protocols: conventional versus ultra-rush.
Selcuk A; Baysan A; Yesillik S; Demirel F; Kartal O; Gulec M; Musabak U; Sener O
Ann Med; 2022 Dec; 54(1):2321-2325. PubMed ID: 36111408
[TBL] [Abstract][Full Text] [Related]
37. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice.
Bonifazi F; Jutel M; Biló BM; Birnbaum J; Muller U;
Allergy; 2005 Dec; 60(12):1459-70. PubMed ID: 16266376
[TBL] [Abstract][Full Text] [Related]
38. Exclusive Bee Venom Allergy: Risk Factors and Outcome of Immunotherapy.
Rosman Y; Nashef F; Cohen-Engler A; Meir-Shafrir K; Lachover-Roth I; Confino-Cohen R
Int Arch Allergy Immunol; 2019; 180(2):128-134. PubMed ID: 31216540
[TBL] [Abstract][Full Text] [Related]
39. Gene expression analysis in predicting the effectiveness of insect venom immunotherapy.
Niedoszytko M; Bruinenberg M; de Monchy J; Wijmenga C; Platteel M; Jassem E; Oude Elberink JN
J Allergy Clin Immunol; 2010 May; 125(5):1092-7. PubMed ID: 20334904
[TBL] [Abstract][Full Text] [Related]
40. [Rush hyposensitization with Hymenoptera venoms. Tolerance and results of therapy].
Przybilla B; Ring J; Griesshammer B; Braun-Falco O
Dtsch Med Wochenschr; 1987 Mar; 112(11):416-24. PubMed ID: 3816590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
